Alzheimer's and Dementia: Translational Research and Clinical Interventions
ESCI-ISI SCOPUS (2015-2025)
2352-8737
Mỹ
Cơ quản chủ quản: WILEY , John Wiley & Sons Inc.
Lĩnh vực:
Psychiatry and Mental HealthNeurology (clinical)
Phân tích ảnh hưởng
Các bài báo tiêu biểu
Inflammation as a central mechanism in Alzheimer's diseaseAbstract Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized by cognitive decline and the presence of two core pathologies, amyloid β plaques and neurofibrillary tangles. Over the last decade, the presence of a sustained immune response in the brain has emerged as a third core pathology in AD. The sustained activation of the br... ...
Tập 4 Số 1 - Trang 575-590 - 2018
Alzheimer's disease drug development pipeline: 2018Abstract Introduction Treatments for Alzheimer's disease (AD) are needed due to the growing number of individuals with preclinical, prodromal, and dementia forms of AD. Drug development for AD therapies can be examined by inspecting the drug development pipeline as represented on clinicaltrials.gov . Methods Clinicaltrials.gov was assessed as of January 30, 2018 to determine AD therapies represented in phase I, phase II, and phase III.Results There are 112 agents in the current AD treatment pipeline. There are 26 agents in 35 trials in phase III, 63 agents in 75 trials in phase II, and 23 agents in 25 trials in phase I. A review of the mechanisms of actions of the agents in the pipeline shows that 63% are disease‐modifying therapies, 22% are symptomatic cognitive enhancers, and 12% are symptomatic agents addressing neuropsychiatric and behavioral changes. Trials in phase III are larger and longer than phase II or phase I trials, particularly those involving disease‐modifying agents. Comparison with the 2017 pipeline shows that there are four new agents in phase III, 14 in phase II, and eight in phase I. Inspection of the use of biomarkers as revealed on hiện toàn bộ
Tập 4 Số 1 - Trang 195-214 - 2018
Alzheimer's disease drug development pipeline: 2017Abstract Introduction There is an urgent need to develop new treatments for Alzheimer's disease (AD) and to understand the drug development process for new AD therapies. Methods We assessed the agents in the AD pipeline as documented in hiện toàn bộ
Tập 3 Số 3 - Trang 367-384 - 2017
Sedentary behavior as a risk factor for cognitive decline? A focus on the influence of glycemic control in brain healthAbstract Cognitive decline leading to dementia represents a global health burden. In the absence of targeted pharmacotherapy, lifestyle approaches remain the best option for slowing the onset of dementia. However, older adults spend very little time doing moderate to vigorous exercise and spend a majority of time in sedentary behavior. Sedentary behavior has been li... ...
Tập 3 Số 3 - Trang 291-300 - 2017
Accelerating drug development for Alzheimer's disease through the use of data standardsAbstract Introduction The exceedingly high rate of failed trials in Alzheimer's disease (AD) calls for immediate attention to improve efficiencies and learning from past, ongoing, and future trials. Accurate, highly rigorous standardized data are at the core of meaningful scientific research. Data standards allow for proper integrat...
Tập 3 - Trang 273-283 - 2017
Amyloid‐associated increases in longitudinal report of subjective cognitive complaintsAbstract Introduction To investigate whether baseline subjective cognitive complaints (SCCs) predict longitudinal decline on neuropsychological testing and whether SCC increases longitudinally, in the setting of high levels of amyloid burden. Methods Two hundred seventy‐ni...
Tập 4 - Trang 444-449 - 2018
NGP 555, a γ‐secretase modulator, shows a beneficial shift in the ratio of amyloid biomarkers in human cerebrospinal fluid at safe dosesAbstract Introduction Currently, there is no cure for Alzheimer's disease (AD), and it is widely accepted that AD is a complex disease with multiple approaches necessary to prevent and treat the disease. Methods Using amyloid biomarkers in human cerebrospinal fluid, pharma...
Tập 5 - Trang 458-467 - 2019
Amyloid‐β oligomers suppress subunit‐specific glutamate receptor increase during LTPAbstract Introduction Amyloid‐β oligomers (AβOs) are assumed to impair the ability of learning and memory by suppressing the induction of synaptic plasticity, such as long‐term potentiation (LTP) in the early stage of Alzheimer's disease. However, the direct molecular mechanism of how AβOs affect excitatory synaptic plasticity remai...
Tập 5 - Trang 797-808 - 2019
Promising results from a pilot study to reduce distress in Vietnamese American dementia and memory loss caregiversAbstract Introduction This study developed and examined the feasibility of a culturally tailored, evidence‐based skill‐building program to reduce stress and depression of Vietnamese American dementia caregivers. Methods This pilot randomized controlled trial included prete...
Tập 5 - Trang 319-327 - 2019
Effect of zerumbone on scopolamine‐induced memory impairment and anxiety‐like behaviours in ratsAbstract Introduction We investigated the effects of zerumbone (1 and 10 mg/kg) against hyperactivity, anxiety and memory impairment in scopolamine‐induced dementia in Sprague‐Dawley rats. Methods Open field tests, elevated plus maze and Morris water maze were performed to...
Tập 5 - Trang 637-643 - 2019